Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Nature communications·2026

Same author

A generalizable system for antigenic peptide targeting across HLA-I allotypes.

bioRxiv : the preprint server for biology·2026

Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026

Same author

CD19 CAR T cells for B-ALL with EMD.

Blood advances·2026

Same author

Suppression of the fat storage defect of <i>C. elegans dbl-1/BMP</i> signaling mutants correlates with improved survival on a bacterial pathogen.

microPublication biology·2026

Same author

Thermally Controlled Chiral Supramolecular Polymorphism in Water.

Angewandte Chemie (International ed. in English)·2026

Search research articles

Related Experiment Video

Updated: Jun 28, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.

David Steffin^1,2,3,4, Nisha Ghatwai^1,2, Antonino Montalbano^1,2

¹Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.

Research Square

|April 22, 2024

Summary

Interleukin-15 (IL15) co-expression significantly improved CAR T cell efficacy against solid tumors. This enhanced CAR T cell therapy demonstrated increased expansion and antitumor activity in patients.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Jun 28, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Immunotherapy
Oncology
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T cells show limited efficacy in solid tumors.
Interleukin-15 (IL15) is known to enhance T lymphocyte survival and CAR T cell antitumor properties.
Glypican-3 (GPC3) is a target antigen expressed in several solid cancers.

Approach:

Evaluated the safety and efficacy of GPC3-CAR T cells in human patients (Cohort 1).
Assessed the impact of IL15 co-expression (15.CAR T cells) on GPC3-CAR T cell expansion and antitumor activity (Cohort 2).
Investigated the molecular mechanisms underlying treatment response, including epigenetic and signaling pathway changes.

Key Points:

GPC3-CAR T cells alone were safe but ineffective in solid tumors.
Co-expression of IL15 with GPC3-CAR T cells (15.CAR) significantly increased cell expansion and demonstrated antitumor activity (33% response rate, 66% disease control rate).
Cytokine release syndrome was manageable with a safety switch; responders showed specific epigenetic and gene expression profiles in tumor-infiltrating T cells.

Conclusions:

IL15 co-expression enhances the expansion, intratumoral survival, and antitumor activity of GPC3-CAR T cells in patients with GPC3-expressing solid tumors.
This strategy represents a promising advancement for CAR T cell therapy in solid malignancies.
Further research into the identified molecular pathways could optimize future immunotherapy strategies.